South Korean medical aesthetics company Jeisys Medical (Jeisys) has announced a KRW 30 billion (approx. USD 23 million) fundraising round, primarily to refinance short-term debt and support the global rollout of its botulinum toxin product, Jeisys The Toxin. The move signals the company's aggressive push into China and the US, two of the world's largest aesthetic toxin markets.
Fundraising details
Jeisys Medical announced on June 19 that its board decided to issue KRW 23 billion in convertible bonds (CBs) and KRW 7 billion in convertible preferred shares (CPS), both with a 0% coupon rate. The conversion price is set 10% above the current stock price, minimizing dilution for existing shareholders. The issuance is structured to strengthen the company's balance sheet ahead of upcoming debt maturity.
Debt repayment and China market entry
Of the total funds, KRW 20 billion will be used to repay bonds maturing on July 6. The remaining KRW 10 billion will be allocated to launching Jeisys The Toxin in China. Jeisys has a 10-year supply agreement with Chinese partner Huadong Aesthetic for botulinum toxin worth KRW 550 billion. The product is expected to launch in the second half of 2027, pending NMPA sales approval.
US and broader global expansion
Jeisys has successfully completed Phase 2 clinical trials for its botulinum toxin injectable with the US FDA, paving the way for entry into the world's largest aesthetic market. The company also plans to expand partnerships in Thailand, Turkey, and other key markets to establish a global footprint.
What buyers should watch
Distributors and clinic buyers should monitor Jeisys The Toxin's NMPA approval timeline in China, as well as its US FDA Phase 3 progress. The company's 0% coupon CB/CPS structure suggests strong investor confidence. For overseas buyers, the product's competitive pricing and supply chain reliability will be critical factors once commercialized.
Source: Read the original report | Published: June 19, 2026